GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum Genomics (OTCPK:QNNTF) » Definitions » Debt-to-EBITDA

Quantum Genomics (Quantum Genomics) Debt-to-EBITDA : -0.08 (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Quantum Genomics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quantum Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. Quantum Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $3.21 Mil. Quantum Genomics's annualized EBITDA for the quarter that ended in Dec. 2022 was $-39.53 Mil. Quantum Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Quantum Genomics's Debt-to-EBITDA or its related term are showing as below:

QNNTF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.355
* Ranked among companies with meaningful Debt-to-EBITDA only.

Quantum Genomics Debt-to-EBITDA Historical Data

The historical data trend for Quantum Genomics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum Genomics Debt-to-EBITDA Chart

Quantum Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.16 -0.10

Quantum Genomics Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.24 -0.12 -0.15 -0.08

Competitive Comparison of Quantum Genomics's Debt-to-EBITDA

For the Biotechnology subindustry, Quantum Genomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum Genomics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quantum Genomics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quantum Genomics's Debt-to-EBITDA falls into.



Quantum Genomics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quantum Genomics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 3.214) / -31.992
=-0.10

Quantum Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 3.214) / -39.532
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2022) EBITDA data.


Quantum Genomics  (OTCPK:QNNTF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Quantum Genomics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quantum Genomics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum Genomics (Quantum Genomics) Business Description

Traded in Other Exchanges
Address
33, Rue Marbeuf, Paris, FRA, 75008
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.